Terray Therapeutics
Terray Therapeutics raises $120M Series B at $600M valuation
Terray Therapeutics: Series B Funding Round
Terray Therapeutics has successfully raised $120M in Series B funding, reaching a valuation of $600M.
Company Overview
AI platform for small molecule drug discovery and development
Funding Details
The Series B round was led by Bedford Ridge Capital, with participation from NVentures.
Company Information
- Headquarters: Los Angeles, CA
- Founded: 2018
- Employees: 150+
- Category: Biotech
Investment
Terray Therapeutics plans to use the funds to accelerate product development, expand its team, and scale operations globally.
About the Investors
- Bedford Ridge Capital: Verified investor in Series B
- NVentures: Verified investor in Series B
Company Info
Investors (2)
Share
Related Reports
AusperBio Raises $73M Series B
Biotech company developing AHB-137, an antisense oligonucleotide for chronic hepatitis B treatment entering phase 2 trials
Orna Therapeutics Raises $251M Series B
Biotechnology company developing circular RNA therapeutics for cancer, genetic diseases, and infectious diseases
Forge Biologics Raises $120M Series C
Gene therapy CDMO providing manufacturing and development services for AAV-based genetic medicines
Turn your sales ideas into reality today
Start your 14-day Pro trial today. No credit card required.
Start building for free